| Long-Term Results of Fixed High-Dose I-131 Treatment for Toxic Nodular Goiter: Higher Euthyroidism Rates in Geriatric Patients | Gül Ege AKTAŞ,Halil Turgut TUROĞLU,TANJU YUSUF ERDİL,SABAHAT İNANIR,FUAT DEDE | 94–99 |
| Effectiveness of Radioiodine Treatment for Toxic Nodular Goiter | Hatice ŞAKI,ARZU CENGİZ,YAKUP YÜREKLİ | 100–104 |
| Assessment of Gastric Accommodation in Patients with Functional Dyspepsia by 99mTc-Pertechtenate Single Photon Emission Computed Tomography Imaging: Practical but not Widely Accepted | Taghi AMİRİANİ,Hamid JAVADİ,Tahereh RAİATNAVAZ,Ali PASHAZADEH MAHMOUD,Shahriar SEMNANİ,Seyed Masoud TABİB,Majid ASSADİ | 105–109 |
| Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain | Ashraf FAKHARİ,Amir R. JALİLİAN,Hassan YOUSEFNİA,Saeed SHANEHSAZZADEH,Ali Bahrami SAMANİ,Fariba JOHARİ-DAHA2,Mehdi ARDESTANİ SHAFİEE,Ali KHALAJ | 110–119 |
| Does Metastatic Lymph Node SUVmax Predict Survival in Patients with Esophageal Cancer? | Betül VATANKULU,Yasemin ŞANLI,Esra SAĞLAM KAYTAN,SERKAN KUYUMCU,ZEYNEP GÖZDE ÖZKAN,Ebru YILMAZ,Sevim PURİSA,Işık ADALET | 120–127 |
| Uptake Difference by Somatostatin Receptors in a Patient with Neuroendocrine Tumor: 99mTc-Octreotide Uptake in the Lung without Uptake in Liver Lesions | Elahe PİRAYESH,Mahasti AMOUİ,Majid ASSADİ | 128–131 |
| 18F-NaF Positive Bone Metastases of Non 18F-FDG Avid Mucinous Gastric Cancer | ÇİĞDEM SOYDAL,ELGİN ÖZKAN,NURİYE ÖZLEM KÜÇÜK,KEMAL METİN KIR | 132–134 |
| Graves Disease Induced by Radioiodine Therapy for Toxic Nodular Goiter: A Case Report | YAKUP YÜREKLİ,ARZU CENGİZ,ENGİN GÜNEY | 135–137 |